Shares of Aeluma surged 10.2% to $15.64 Tuesday morning, bucking a brutal selloff across semiconductor stocks, after the company signed a non-binding letter of intent for up to $30 million in CHIPS Act R&D funding from the U.S. Department of Commerce. The question for investors: does a government promise — one that hasn't yet turned into a binding contract — change the math for a company generating just $5.2 million in trailing revenue?
• Washington Is Betting on Aeluma's Alternative Chip-Making Approach, and That Stamps Credibility on a Young Company. Aeluma will receive up to $30 million to develop large-diameter, indium-phosphide-free substrate technology used to fabricate photodetectors and lasers for AI photonic interconnects.
The award is part of a broader $874 million Commerce Department package covering seven companies. For a firm with just $5.20 million in trailing twelve-month revenue and $6 million in losses , a $30 million federal commitment — nearly six times annual sales — is transformative if it converts to a binding agreement. The award is still subject to due diligence and Commerce Secretary approval.
• The Money Could Extend Aeluma's Runway Without Diluting Shareholders. The company holds $37.78 million in cash against just $1.09 million in debt. But shares outstanding rose 37% last year , and Aeluma has a $50 million at-the-market stock offering in place that lets it sell shares at any time. Government R&D grants are non-dilutive — they don't require giving up ownership — making this a far cheaper way to fund research than issuing new stock. That distinction matters for existing shareholders watching their stakes shrink.
• Revenue Today Is Almost Entirely From Government Contracts, Not Commercial Customers. Aeluma's current revenues are limited to government R&D contracts, with no commercial adoption or material revenue visibility yet.
Its technology has been validated by NASA grants, Pentagon contracts, and a partnership with Tower Semiconductor , but no major OEM contracts have been secured yet. Until a large device maker signs on, the stock trades on promise, not proven demand.
• The Valuation Already Prices In Enormous Success. At today's price, Aeluma trades at roughly 46 times trailing sales — a staggering multiple for a company that recently narrowed its full-year revenue forecast to just $4.2–$4.6 million.
Share count has swelled 38% in a year. The CHIPS Act letter validates the technology's strategic importance, but converting Washington's endorsement into commercial contracts remains the make-or-break milestone investors should watch.